生物製剤受託製造の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

生物製剤受託製造市場の世界需要は、2023年の167億7,000万米ドルから2032年には約479億2,000万米ドルの市場規模に達すると推定され、調査期間2024～2032年のCAGRは11.07%です。

生物製剤の受託製造とは、バイオ医薬品の生産・製造工程を専門の受託製造機関（CMO）に委託することです。生物製剤は、タンパク質、抗体、ワクチン、細胞ベースの治療薬など、生物由来の複雑な治療製品です。製薬会社、バイオテクノロジー企業、学術機関は、CMOの専門知識、能力、インフラを活用することで、効率的かつコスト効率よく大規模に生物製剤を製造することができます。

市場力学

生物学的製剤の効能と個別化医療アプローチによる需要の増加は、効率的な製造能力の必要性を煽っています。専門の製造受託機関（CMO）に生物製剤の製造を委託することで、製薬会社はコスト効率と柔軟性を高め、コアコンピタンスに集中し、需要に応じて生産量を調整することができます。この製造における厳格な規制基準と品質保証はCMOによって満たされ、規制への準拠と製品の安全性と有効性の維持が保証されます。バイオプロセスにおける技術の進歩は、生物製剤製造の効率性と生産性をさらに高め、製薬会社とCMOの協力的パートナーシップは技術革新を推進し、プロセスを合理化します。バイオ医薬品産業の世界の市場拡大は、生物製剤の重視の高まりとともに、信頼性が高く拡張性のあるソリューションの必要性を強めています。

この調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、競合の魅力を世界レベルで評価するのに役立ちます。さらに、これらのツールは生物製剤受託製造の世界市場における各セグメントを包括的に評価することもできます。生物製剤受託製造業界の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

生物製剤受託製造市場レポートのこのセクションでは、国および地域レベルのセグメントに関する詳細なデータを提供し、それによって戦略家がそれぞれの製品またはサービスのターゲット層を特定する上で、今後の機会を支援します。

製品別

• MAB
• 組み換えタンパク質
• その他

適応症別

• 腫瘍学
• 免疫疾患
• 心血管疾患
• 血液疾患
• その他

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおける生物製剤受託製造市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、本レポートは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 生物製剤受託製造- 産業分析

• イントロダクション：市場力学
• 市場促進要因
• 市場抑制要因
• 機会
• 業界動向
• ポーターのファイブフォース分析
• 市場の魅力分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカーリスト
  • 主要原材料の価格動向
• 潜在的バイヤーのリスト
• マーケティングチャネル
  • ダイレクトマーケティング
  • インダイレクトマーケティング
  • マーケティングチャネル発展動向

第5章 世界の生物製剤受託製造市場分析：製品別

• 製品別概要
• 実績データと予測データ
• 製品別分析
• MAB
• 組み換えタンパク質
• その他

第6章 世界の生物製剤受託製造市場分析：適応症別

• 適応症別概要
• 実績データと予測データ
• 適応症別分析
• がん領域
• 免疫疾患
• 心血管疾患（CVDs）
• 血液疾患
• その他

第7章 生物製剤受託製造の世界市場分析：地域別

• 地域別展望
• イントロダクション
• 北米売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米国別
  • 米国
  • カナダ
  • メキシコ
• 欧州売上分析
  • 概要、実績と予測
  • 欧州セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他欧州
• アジア太平洋売上分析
  • 概要、実績と予測
  • アジア太平洋：セグメント別
  • アジア太平洋：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他アジア太平洋
• ラテンアメリカ売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他ラテンアメリカ
• 中東・アフリカ売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東とアフリカ

第8章 生物製剤受託製造企業の競合情勢

• 生物製剤受託製造市場の競合
• パートナーシップ/提携/合意
• 合併・買収
• 新製品上市
• その他の開発

第9章 企業プロファイル

• 上位企業の市場シェア分析
• 市場集中度
• Wuxi Biologics
• Abzena Ltd.
• Fujifilm Diosynth Biotechnologies
• BI BioXcellence
• Lonza Group AG
• Boehringer Ingelheim GmbH
• Samsung Biologics
• Abbvie
• Catalent
• Bioreliance
• Eurofins CDMO
• Thermo Fischer（Patheon）

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Product (USD MN)
• MABs Market Sales by Geography (USD MN)
• Recombinant Protein Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Indication (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Immunological Disorders Market Sales by Geography (USD MN)
• Cardiovascular Disorders (CVDs) Market Sales by Geography (USD MN)
• Hematological Disorders Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Biologics Contract Manufacturing Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Biologics Contract Manufacturing Report
• Market Research Process
• Market Research Methodology
• Global Biologics Contract Manufacturing Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Product
• Market Attractiveness Analysis by Indication
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Product (USD MN)
• MABs Market Sales by Geography (USD MN)
• Recombinant Protein Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Indication (USD MN)
• Oncology Market Sales by Geography (USD MN)
• Immunological Disorders Market Sales by Geography (USD MN)
• Cardiovascular Disorders (CVDs) Market Sales by Geography (USD MN)
• Hematological Disorders Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Biologics Contract Manufacturing Market is presumed to reach the market size of nearly USD 47.92 Billion by 2032 from USD 16.77 Billion in 2023 with a CAGR of 11.07% under the study period 2024 - 2032.

Biologics contract manufacturing refers to the outsourcing of the production and manufacturing processes of biopharmaceutical products to specialized contract manufacturing organizations (CMOs). Biologics are complex therapeutic products derived from living organisms, such as proteins, antibodies, vaccines, and cell-based therapies. It allows pharmaceutical companies, biotechnology firms, and academic institutions to leverage the expertise, capabilities, and infrastructure of CMOs to efficiently and cost-effectively produce biologics on a large scale.

MARKET DYNAMICS

The increasing demand for biological drugs, driven by their efficacy and personalized medicine approaches, fuels the need for efficient manufacturing capabilities. Outsourcing biologics production to specialized contract manufacturing organizations (CMOs) offers cost efficiency and flexibility for pharmaceutical companies, allowing them to focus on core competencies and adjust production volumes based on demand. The stringent regulatory standards and quality assurance in this manufacturing are met by CMOs, ensuring compliance with regulations and maintaining product safety and efficacy. Technological advancements in bioprocessing further enhance the efficiency and productivity of biologics manufacturing, and collaborative partnerships between pharmaceutical companies and CMOs drive innovation and streamline processes. The global market expansion of the biopharmaceutical industry, along with the growing emphasis on biologics, reinforces the need for reliable and scalable solutions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biologics contract manufacturing. The growth and trends of biologics contract manufacturing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the biologics contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• MABs
• Recombinant Protein
• Others

By Indication

• Oncology
• Immunological Disorders
• Cardiovascular Disorders (CVDs)
• Hematological Disorders
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Biologics Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the biologics contract manufacturing market include Wuxi Biologics; Abzena Ltd.; FUJIFILM Diosynth Biotechnologies; BI BioXcellence; Lonza Group AG; Boehringer Ingelheim GmbH; Samsung Biologics; Abbvie; Catalent; Bioreliance; Eurofins CDMO; Thermo Fischer (Patheon). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . BIOLOGICS CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY PRODUCT

• 5.1 Overview by Product
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Product
• 5.4 MABs Historic and Forecast Sales by Regions
• 5.5 Recombinant Protein Historic and Forecast Sales by Regions
• 5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY INDICATION

• 6.1 Overview by Indication
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Indication
• 6.4 Oncology Historic and Forecast Sales by Regions
• 6.5 Immunological Disorders Historic and Forecast Sales by Regions
• 6.6 Cardiovascular Disorders (CVDs) Historic and Forecast Sales by Regions
• 6.7 Hematological Disorders Historic and Forecast Sales by Regions
• 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE BIOLOGICS CONTRACT MANUFACTURING COMPANIES

• 8.1. Biologics Contract Manufacturing Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF BIOLOGICS CONTRACT MANUFACTURING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Wuxi Biologics
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Abzena Ltd.
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Fujifilm Diosynth Biotechnologies
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. BI BioXcellence
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Lonza Group AG
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Boehringer Ingelheim GmbH
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Samsung Biologics
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Abbvie
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Catalent
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. Bioreliance
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments
• 9.13. Eurofins CDMO
  • 9.13.1. Company Overview
  • 9.13.2. Company Revenue
  • 9.13.3. Products
  • 9.13.4. Recent Developments
• 9.14. Thermo Fischer (Patheon)
  • 9.14.1. Company Overview
  • 9.14.2. Company Revenue
  • 9.14.3. Products
  • 9.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies